buy lsd online Perth, LSD acid tabs for sale Perth, LSD for sale Canberra, Buy LSD in Darwin, Hobart, Cairns, Townsville, Mildura, Devonport LSD was introduced as a commercial medication under the trade-name Delysid for various psychiatric uses in 1947. LSD was brought to the attention of the United States in 1949 by Sandoz Laboratories because they …
LSD acid tabs for sale Perth
Buy lsd acid tabs Perth, LSD acid tabs for sale online perth, buy acid tabs online Queensland, Order lsd tabs in Perth, Buy LSD blotters, buy lsd sheets
Clinical trials and specialist training
In the spirit of Dr John Cade, a number of psychedelic studies are underway at Monash with funding from a variety of sources, including industry, philanthropy, government, and the University.
The Clinical Psychedelic Research Lab at Monash, the first psychedelic medicine lab in Australia, is establishing several clinical studies.
One of these trials will investigate whether psilocybin-assisted psychotherapy can safely and effectively treat severe and entrenched anxiety; another will look at a form of psychotherapy facilitated by MDMA – an “entactogen” rather than a classic psychedelic – in the treatment of severe PTSD.
These drug treatments are delivered alongside psychotherapy, and trial therapists have undergone specialised training to facilitate the long sessions.
The group’s leader, Dr Liknaitzky, is a research fellow at the Turner Institute for Brain and Mental Health, and Department of Psychiatry. His group has also developed and delivered the first applied psychedelic therapist training in Australia, obtained the first industry funding and partnership for clinical psychedelic research, and has numerous local and international collaborations with leading experts in psychedelic science and treatment.
“The bottom line for me is that mental ill-health was always a big problem before COVID, and it’s only getting worse. The time is right to link up these activities and drive novel neuromedicine research for psychiatric illnesses.” – Arthur Christopoulos, Dean, Monash Faculty of Pharmacy and Pharmaceutical Sciences
Another of Monash’s psychedelic trials, PSICONNECT, in a healthy population, will be led by Associate Professor Adeel Razi. This trial will use brain imaging to record, in real time, the peak effects of psilocybin on the brains of healthy subjects. This trial is looking to decipher the connection between the psychological and neurological effects of psilocybin (that is, how it works) in a normal functioning brain. This is a poorly-understood area.
Other Monash groups are investigating the use of psilocybin in preclinical studies, and conducting survey and qualitative research on psychedelic use.
A multidisciplinary approach
Further trials and translational research studies are in advanced planning. Monash experts from across the pharmaceutical sciences, psychiatry, psychometrics, psychotherapy, risk mitigation, governance, behaviour change, computational neuroscience, and mental health are involved.
Some of the central questions are:
Can these prohibited substances, combined with psychotherapy, dramatically improve outcomes across a range of poorly-treated mental health disorders?
Can a better understanding of the causes of mental ill-health be found? Will a process of potentially addressing more fundamental causes of psychological distress than surface symptoms show us more about the illnesses themselves. Buy lsd acid tabs Perth, LSD acid tabs for sale online perth, buy acid tabs online Queensland, Order lsd tabs in Perth, Buy LSD blotters, buy lsd sheets
Can we discover more about what happens at a molecular and cellular level in the brain after taking psychedelic substances, and can that knowledge help those who suffer?
And, do psychedelic-assisted psychotherapies represent a new form of treatment that can directly and effectively target both the brain and mind simultaneously? Will this allow mental health treatments to finally catch up to those available for other diseases, such as cancer and heart-disease, which now have new science and more targeted therapies?
These studies appear crucial in an ongoing mental health crisis, with mental illness being this century’s leading cause of disability.
“There is a vast unmet need for safe and effective medicines for mental health disorders,” says Dr Chris Langmead, of FPPS’s Monash Institute of Pharmaceutical Sciences (MIPS).
Dr Langmead is co-lead of the Neuroscience and Mental Health Therapeutic Program within MIPS.
“Poor mental health represents a growing problem in our society, and it’s being increasingly recognised as such,” he says.
“There’s been rising expenditure in programs trying to address mental health, but the extra spending is not addressing the rates of disorders that we see.”